NCT05351788View on ClinicalTrials.gov

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

April 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

SKB264

SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)

DRUG

KL-A167

KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)

DRUG

Carboplatin

Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)

DRUG

Cisplatin

Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)

Trial Locations (2)

510060

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY